EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Patients with Multiple Myeloma with Ibandronate and Correlation with Type I Collagen Degradation Product



Treatment of Patients with Multiple Myeloma with Ibandronate and Correlation with Type I Collagen Degradation Product



Blood 100(11): Abstract No 1547, November 16



The bisphosphonate ibandronate (IB) is found to reduce, significantly, the occurrence of osteolytic bone lesions in a murine model of myeloma bone disease. The carboxy-terminal telopeptide of type I collagen (ICTP) is a serum marker of bone metastasis in patients (pts) with solid tumors and can be used as a serum marker of bone metabolism in multiple myeloma (MM). The aim of the current study is to investigate the efficacy and safety of IB treatment in MM pts with osteolytic lesions and also evaluate serum ICTP levels post IB treatment. Sixteen MM pts with osteolytic lesions, 6 M and 10 F, with a median age of 72 years (range 47-86 ) were treated with IB at a dose of 4 mg, administered by IV infusion over 1h, every 4 weeks for at least 12 months. IB was administered approximately one week after the end of the patient's chemotherapy. None of the pts had renal or hepatic dysfunction or metabolic bone disease. Pts were clinically evaluated before, during and after IB administration for possible occurrence of side effects. Routine serum chemical screening including beta-2 microglobulin (beta2-m), calcium and alkaline phosphate and radiographic evaluation of osteolytic lesions were performed during the study. Serum samples were taken before each IB administration and stored frozen until used for measurement of ICTP levels with b-CrossLaps/serum immunoassay. Clinical improvement of skeletal pains was observed after the first cycle of IB treatment with total pain relief during the third month. Radiographic evaluation after six months of treatment showed partial remission of osteolytic bone lesions. There were no major side effects after IB administration except for mild vomiting in two pts. Haematologic, hepatic or renal dysfunction were not detected except for transient hypocalcaemia and hypophosphataemia in 5 pts (31%). High mean serum ICTP levels were documented only in 3/16 pts ( 1,513 +-0,31 ng/ml ) while the remainder of pts had levels within normal limits ( 0,392 +- 0,31 ng/ml). High serum ICTP levels were correlated with progressive osteolytic bone disease and elevated serum levels of beta2-m, hypercalcaemia, bad performance status and stage of disease. Treatment with IB, in these fore mentioned 3 pts, resulted in reducing the high ICTP levels in normal limits even after the first cycle of treatment ( pre: 1,513 +-0,31 ng/ml, post: 0,881 +- 0,38 ng/ml ). If the decrease of serum ICTP levels caused by IB treatment is confirmed, in future trials, with a greater number of pts, serum ICTP levels can be used as a prognostic index in MM. Treatment of MM pts with osteolytic lesions with IOTABETA is well tolerated and probably may decrease serum ICTP levels.

(PDF 0-2 workdays service: $29.90)

Accession: 035980568

Download citation: RISBibTeXText



Related references

Oral ibandronate preceded by an intravenous (i.v.) ibandronate loading dose in patients with breast cancer and bone metastases or multiple myeloma: phase III results. Journal of Clinical Oncology 23(16_suppl): 8060-8060, 2016

Renal impairment in multiple myeloma patients following zoledronic acid or ibandronate treatment. Journal of Clinical Oncology 24(18_suppl): 17501-17501, 2016

Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. Acta Haematologica 116(3): 165-172, 2006

Serum activity of type 5B ACP and biochemical markers of type I collagen degradation in osteoporotic men with Klinefelters syndrome treated with an intravenous ibandronate. Calcified Tissue International 70(4): 279, April, 2002

The compare study - An assessment of renal toxicity of ibandronate and zoledronic acid in multiple myeloma patients. Bone 42(supp-S1): 0, 2008

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. British Journal of Haematology 111(1): 283-286, October, 2000

Effects of intravenous ibandronate therapy on skeletal related events and survival in patients with advanced multiple myeloma. Blood 92(10 SUPPL 1 PART 1-2): 106A, Nov 15, 1998

Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series. Onkologie 32(8-9): 482-486, 2009

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. Journal of Cancer Research and Therapeutics 6(1): 31-35, 2010

Increased levels of urinary N-telopeptide of type I collagen correlate with reduced survival in patients with advanced multiple myeloma. 2007

The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma. Leukemia & Lymphoma 46(12): 1749-1753, 2005

Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. British Journal of Rheumatology 33(11): 1012-1016, 1994

Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). British Journal of Haematology 96(1): 103-110, 1997

Connective tissue components in serum in multiple myeloma: Analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. American Journal of Hematology 46(3): 173-178, 1994